ARTICLE | Clinical News
Fiasp regulatory update
November 17, 2016 2:33 PM UTC
EMA's CHMP recommended approval of Fiasp insulin aspart from Novo Nordisk to treat diabetes in adults. The company expects a decision from the European Commission in 1Q17. Fiasp is a faster-acting ins...
BCIQ Company Profiles
BCIQ Target Profiles